NCT07516886 Prognostic Value of Early Postoperative Prostate-Specific Antigen for Oncological Outcomes After Radical Prostatectomy
| NCT ID | NCT07516886 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Lithuanian University of Health Sciences |
| Condition | Prostate Cancer (Post Prostatectomy) |
| Study Type | OBSERVATIONAL |
| Enrollment | 500 participants |
| Start Date | 2024-01-22 |
| Primary Completion | 2039-07 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 500 participants in total. It began in 2024-01-22 with a primary completion date of 2039-07.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This prospective observational study aims to evaluate the prognostic significance of early postoperative prostate-specific antigen (PSA) levels in patients undergoing radical prostatectomy for prostate cancer. No investigational interventions will be performed. All diagnostic procedures, follow-up assessments, and treatments will be conducted in accordance with standard clinical practice and established prostate cancer management guidelines. Participation in the study will not influence treatment decisions.
Eligibility Criteria
Inclusion Criteria: * Patient is an adult biological male. * Patient has morphologically confirmed and untreated prostate cancer. * Patient who will be treated with open, laparoscopic or robot-assisted laparoscopic radical prostatectomy. * Patient is informed about this observational study and has signed the informed consent form. Exclusion Criteria: * Patient has radiologically of morphologically confirmed prostate cancer metastases before the operation. * Patient received neoadjuvant prostate cancer treatment. * Patient is set to receive adjuvant treatment. * Patient has any contraindications for the operation.
Contact & Investigator
Daimantas Milonas, MD, PhD, Professor
PRINCIPAL INVESTIGATOR
Lietuvos sveikatos mokslų universitetas
Frequently Asked Questions
Who can join the NCT07516886 clinical trial?
This trial is open to male participants only, aged 18 Years or older, studying Prostate Cancer (Post Prostatectomy). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07516886 currently recruiting?
Yes, NCT07516886 is actively recruiting participants. Contact the research team at gustas.sas@gmail.com for enrollment information.
Where is the NCT07516886 trial being conducted?
This trial is being conducted at Kaunas, Lithuania.
Who is sponsoring the NCT07516886 clinical trial?
NCT07516886 is sponsored by Lithuanian University of Health Sciences. The principal investigator is Daimantas Milonas, MD, PhD, Professor at Lietuvos sveikatos mokslų universitetas. The trial plans to enroll 500 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.